Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carina Lynn, Gehlert"'
Autor:
Malgorzata Bobrowicz, Aleksandra Kusowska, Marta Krawczyk, Andriy Zhylko, Christopher Forcados, Aleksander Slusarczyk, Joanna Barankiewicz, Joanna Domagala, Matylda Kubacz, Michal Šmída, Lenka Dostalova, Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pepek, Iwona Baranowska, Anna Szumera-Cieckiewicz, Else Marit Inderberg, Sébastien Wälchli, Monika Granica, Agnieszka Graczyk-Jarzynka, Martyna Majchrzak, Marcin Poreba, Carina Lynn Gehlert, Matthias Peipp, Malgorzata Firczuk, Monika Prochorec-Sobieszek, Magdalena Winiarska
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated. Several RTX
Externí odkaz:
https://doaj.org/article/9a12db941932493e911360585a202c62
Autor:
Ammelie Svea Boje, Lukas Pekar, Katharina Koep, Britta Lipinski, Brian Rabinovich, Andreas Evers, Carina Lynn Gehlert, Steffen Krohn, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Lars Toleikis, Sven Poetzsch, Matthias Peipp, Stefan Zielonka, Katja Klausz
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTNatural killer (NK) cells emerged as a promising effector population that can be harnessed for anti-tumor therapy. In this work, we constructed NK cell engagers (NKCEs) based on NKp30-targeting single domain antibodies (sdAbs) that redirect t
Externí odkaz:
https://doaj.org/article/dab9f66e27944e228e065c4ff4d03f51
Autor:
Marta Lustig, Chilam Chan, J. H. Marco Jansen, Maria Bräutigam, Max A. Kölling, Carina Lynn Gehlert, Niklas Baumann, Simone Mester, Stian Foss, Jan Terje Andersen, Lorenz Bastian, Peter Sondermann, Matthias Peipp, Renate Burger, Jeanette H. W. Leusen, Thomas Valerius
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins (Siglecs) on lympho
Externí odkaz:
https://doaj.org/article/f13e63d75bf54d1d864e6a9a22d95511
Autor:
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Rösner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (A
Externí odkaz:
https://doaj.org/article/ae618aa47a8b4a9b88c4629566076802
Autor:
Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Sebastian Lutz, Nikos Darzentas, Henrik Knecht, Dietrich Herrmann, Monika Brüggemann, Axel J. Scheidig, Katja Weisel, Martin Gramatzki, Matthias Peipp, Katja Klausz
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
To identify new antibodies for the treatment of plasma cell disorders including multiple myeloma (MM), a single-chain Fragment variable (scFv) antibody library was generated by immunizing mice with patient-derived malignant plasma cells. To enrich an
Externí odkaz:
https://doaj.org/article/67012a1ee1a04392926447c7d0107282
Autor:
Katja Klausz, Lukas Pekar, Ammelie Svea Boje, Carina Lynn Gehlert, Steffen Krohn, Tushar Gupta, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Britta Lipinski, Lars Toleikis, Sven Poetzsch, Brian Rabinovich, Matthias Peipp, Stefan Zielonka
Publikováno v:
The Journal of Immunology. 209:1724-1735
In this work, we have generated novel Fc-comprising NK cell engagers (NKCEs) that bridge human NKp30 on NK cells to human epidermal growth factor receptor (EGFR) on tumor cells. Camelid-derived VHH single-domain Abs specific for human NKp30 and a hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56b42a194d0d8ebf19aa29d6f2fda5a
https://doi.org/10.4049/jimmunol.2100970
https://doi.org/10.4049/jimmunol.2100970
Autor:
Fotini Vogiatzi, Julia Heymann, Kristina Müller, Dorothee Winterberg, Aneta Drakul, Thies Rösner, Lennart Lenk, Michelle Heib, Carina Lynn Gehlert, Gunnar Cario, Martin Schrappe, Alexander Claviez, Beat Bornhauser, Jean-Pierre Bourquin, Simon Bomken, Dieter Adam, Fabian-Simon Frielitz, Britta Maecker-Kolhoff, Martin Stanulla, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe
Publikováno v:
Blood Advances. 6:4847-4858
Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma 2 (Bcl-2) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb89ed7b5ade692f1438bd1a04f5d95a
https://doi.org/10.1182/bloodadvances.2022007364
https://doi.org/10.1182/bloodadvances.2022007364
Autor:
Matthias Peipp, Martin Gramatzki, Bernd Clement, Dirk O. Bauerschlag, Andreas Günther, Inken Floerkemeier, Hauke Wilcken, Steffen Krohn, Carina Lynn Gehlert, Christian Kellner, Katja Klausz
P8-D6 is a novel dual inhibitor of human topoisomerase I (TOP1) and II (TOP2) with broad pro-apoptotic antitumor activity. NCI-60 screening revealed markedly improved cytotoxicity of P8-D6 against solid and leukemia cell lines compared with other sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1da6d0e8e73b4e09348a7b5d8e131497
https://doi.org/10.1158/1535-7163.c.6543349.v1
https://doi.org/10.1158/1535-7163.c.6543349.v1
Autor:
Matthias Peipp, Martin Gramatzki, Bernd Clement, Dirk O. Bauerschlag, Andreas Günther, Inken Floerkemeier, Hauke Wilcken, Steffen Krohn, Carina Lynn Gehlert, Christian Kellner, Katja Klausz
Supplementary Figures 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9dbe22b0e070924be809f33addf7faa
https://doi.org/10.1158/1535-7163.22522354
https://doi.org/10.1158/1535-7163.22522354
Autor:
Hauke Wilcken, Dirk Bauerschlag, Bernd Clement, Inken Floerkemeier, Katja Klausz, Martin Gramatzki, Steffen Krohn, Christian Kellner, Matthias Peipp, Andreas Guenther, Carina Lynn Gehlert
Publikováno v:
Molecular Cancer Therapeutics. 21:70-78
P8-D6 is a novel dual inhibitor of human topoisomerase I (TOP1) and II (TOP2) with broad pro-apoptotic antitumor activity. NCI-60 screening revealed markedly improved cytotoxicity of P8-D6 against solid and leukemia cell lines compared with other sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5140012fe3e49dcf1bf959c2d91c36f
https://doi.org/10.1158/1535-7163.mct-21-0119
https://doi.org/10.1158/1535-7163.mct-21-0119